ClinicalTrials.gg
RecruitingNCT05618002Updated Nov 2, 2026

Lemborexant vs Clonidine vs Sedatives to Treat Insomnia in Chronic Pain Patients

An observational study in Chronic Insomnia, Chronic Pain and Restless Leg Syndrome (RLS), sponsored by Salem Anaesthesia Pain Clinic. Recruiting at 1 site in Canada. Open to participants aged 20 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Salem Anaesthesia Pain Clinic · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.
Updated Nov 2, 2026Now RecruitingNow Active, not recruiting+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-crossover
Time perspective
Prospective
Enrollment
250
Ages
20 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada — 21 open to participants now, 26 under way, 1 of them phase 3. Sleep Initiation and Maintenance Disorders · Canada.

Started
2023
with 8 others
Observational
8 of 104
3 open now
Primary completion
2027-06
later than 21 of 25 live
Registered
80th of 104
by date

Among the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada, this one is one of 9 that started in 2023, is one of 8 observational ones, reaches primary completion later than 21 of the 25 other live ones, and was the 80th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

21 of the 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 20 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Sleep Initiation and Maintenance Disorders with a site in Canada, or all of them as a file.
02

Study summary

Prospective observational crossover study of 250 adults undergoing chronic pain management. For insomnia treatment, patients alternate their usual prescribed sedative versus Lemborexant or Clonidine; on alternate nights. Patients use a validated smartwatch and a validated sleep diary to collect data including mood score, sleep score, sleep duration, and adverse effects. Patients complete the diary for 20-25 days. Pain and mood are measured using numeric rating scales. Sleep score is measured using the Likert sleep scale. Within-patient differences are analyzed. Any change in pain, mood, or sleep scores by 2-points is considered significant.

Read the detailed description

Objectives: Chronic pain is associated with insomnia. The first-line therapy for insomnia is cognitive behavioral therapy (CBT-I). The objective of this clinical study is to compare the safety and efficacy of patients' usual night sedatives against Lemborexant or Clonidine. It explores the management of chronic insomnia in patients with chronic pain.

Methods: Prospective observational crossover study of 250 consenting adult patients who are undergoing chronic pain management. For insomnia treatment, each patient takes their usual night sedatives like Zopiclone on alternate nights; alternating with Lemborexant or Clonidine on alternate nights. Each patient's usual night sedative serves as the control or reference. Each patient uses a special validated sleep diary to collect data including pain score, mood score, sleep score, sleep duration, sleep disruptions, sedative type, and adverse effects. Each patient completes the diary for 20-25 days. Pain and mood are measured using the numeric rating scale. Sleep score is measured using the Likert sleep scale. A change in the pain, mood, or sleep scores by 2-points is considered significant. Each patient's usual night sedative serves as the control or reference. Within-patient differences are analysed using 2-sided paired-difference t-test to calculate mean difference and 95% CI. P-value \<0.05 is considered significant.

03

Conditions studied

  • Chronic Insomnia
  • Chronic Pain
  • Restless Leg Syndrome (RLS)
  • Substance Abuse
  • Tremor
  • Vasomotor Symptoms; Hot Flashes
  • Tinnitus
  • Mood Disorders
  • ADHD With Sleep Onset Insomnia

Keywords

  • Sedative
  • Hypnotic
  • Dual orexin receptor antagonist
  • Insomnia
  • CBT-I
  • Lemborexant
  • Clonidine
  • Doxepin
  • Zopiclone
  • Cannabinoid
04

Who can participate

The criteria were revised on the registry on Oct 28, 2026. See what changed

Ages eligible
20 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult chronic pain clinic patients who have severe chronic insomnia; and undergoing medication treatment for insomnia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult chronic pain patients
  • good treatment compliance
  • severe chronic insomnia
  • failure of non-pharmacologic sleep therapy
  • regular night sedative therapy for 3 months or more
  • regular sleep diary
  • regular pain and mood diary
  • for diary review
  • consent for clinical record quality assurance review

Exclusion criteria

Exclusion Criteria:

  • obstructive sleep apnoea
  • (BMI) ≥40
  • organ insufficiency
  • cognitive disorder
  • inability to provide consent
  • major neuropsychiatric disorder
  • unreliable diary
  • cannabis use
  • regular alcohol intake
  • stimulant use
  • substance abuse
  • poor treatment compliance
  • high dose opioid
  • gabapentinoid use
  • other sedative use
  • mild insomina
  • irregular sedative intake
  • regular sedative therapy for less than 3 months
  • previous adverse/allergic reactions to clonidine or zopiclone
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Case-crossover
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • For insomnia treatment, each patient takes their usual sedative on alternate nights versus Lemborexant or Clonidine; on alternate nights. Each patient uses a special validated sleep diary to collect data.

    Also known as: Zopiclone, Clonidine

06

What researchers measure

Primary outcomes

  1. Sleep quality score, objective measurement using the validated Likert sleep scale

    Sleep quality score, using the Likert sleep scale of 0 to 10, low scores indicate poor sleep, high scores indicate better sleep

    Time frame: 3 weeks

Secondary outcomes

  1. Nocturnal pain score, objective measurement using the validated Numeric Pain Rating scale

    Pain score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less pain, high scores indicate worse pain

    Time frame: 3 weeks

  2. Night mood score, objective measurement using the validated Numeric Mood Rating scale

    Mood score, using the Numeric Pain Rating scale of 0 to 10, low scores indicate less mood, high scores indicate worse mood

    Time frame: 3 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Bamgbade OA, Tai-Osagbemi J, Bamgbade DO, Murphy-Akpieyi O, Fadire A, Soni NK, Mumporeze L. Clonidine is better than zopiclone for insomnia treatment in chronic pain patients. J Clin Sleep Med. 2022 Jun 1;18(6):1565-1571. doi: 10.5664/jcsm.9930. PubMed 35112665 ↗

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2027, 53 months after the start.

Of 127 non-industry observational studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 42. This study's planned 53 months is above that.

Counting every sponsor, half of 138 studies reached it within 18 months; a quarter within 4 and three quarters within 40.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Nov 2022 → Jan 2023, primary completion Dec 2025 → Jun 2027 and completion Dec 2025 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2022
First posted
Nov 16, 2022
StartActual
Jan 2, 2023was Nov 2022
Primary completionEst.
Jun 28, 2027was Dec 2025
CompletionEst.
Jun 28, 2027was Dec 2025
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting→Recruiting
changed Oct 28, 2026 · changed Nov 2, 2026
Sites
Salem Anaesthesia Pain Clinic is now Recruiting
Nov 2, 2026
Start date
Nov 8, 2022→Jan 2, 2023
Oct 28, 2026
Primary completion
Dec 11, 2025→Jun 28, 2027
Oct 28, 2026
Study completion
Dec 11, 2025→Jun 28, 2027
Oct 28, 2026
Enrollment
150→250
Oct 28, 2026
Eligibility
2 inclusion criteria edited; 3 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • Editedregular zopiclonenight sedative therapy for 3 months or more
  • Editedregular pain and mood diary
Exclusion criteria
  • Editedother sedative use
  • Editedirregular zopiclonesedative intake
  • Editedregular zopiclonesedative therapy for less than 3 months
Oct 28, 2026
Secondary outcomes
1 edited, 1 added
What changed in the outcomes
  • EditedPainNocturnal pain score, objective measurement using the validated Numeric Pain Rating scaleTime frame: 3 weeks
  • AddedNight mood score, objective measurement using the validated Numeric Mood Rating scaleTime frame: 3 weeks
Oct 28, 2026
Contact
Study contact now listed: added s•••@gmail.com · •••6600. See the current contact
Nov 2, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Salem Anaesthesia Pain Clinic · Surrey, CanadaContact added s•••@gmail.com · •••6600
Nov 2, 2026
Title
Lemborexant vs Zopiclone vs Clonidine forvs Sedatives to Treat Insomnia Treatment in Chronic Pain Patients
Oct 28, 2026
Show all 2 updates
  1. Nov 2, 2026
    Active, not recruiting→Recruiting
    Salem Anaesthesia Pain Clinic is now Recruiting
    Contact Study contact now listed: added s•••@gmail.com · •••6600. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Salem Anaesthesia Pain Clinic · Surrey, CanadaContact added s•••@gmail.com · •••6600
  2. Oct 28, 2026
    Recruiting→Active, not recruiting
    Start date Nov 8, 2022→Jan 2, 2023
    Primary completion Dec 11, 2025→Jun 28, 2027
    Study completion Dec 11, 2025→Jun 28, 2027
    Enrollment 150→250
    Eligibility 2 inclusion criteria edited; 3 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • Editedregular zopiclonenight sedative therapy for 3 months or more
    • Editedregular pain and mood diary
    Exclusion criteria
    • Editedother sedative use
    • Editedirregular zopiclonesedative intake
    • Editedregular zopiclonesedative therapy for less than 3 months
    Secondary outcomes 1 edited, 1 added
    What changed in the outcomes
    • EditedPainNocturnal pain score, objective measurement using the validated Numeric Pain Rating scaleTime frame: 3 weeks
    • AddedNight mood score, objective measurement using the validated Numeric Mood Rating scaleTime frame: 3 weeks
    Title Lemborexant vs Zopiclone vs Clonidine forvs Sedatives to Treat Insomnia Treatment in Chronic Pain Patients
    + 7 other changes: index terms, verification date, description, conditions, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05618002
Lead sponsor
Salem Anaesthesia Pain Clinic
Responsible party
Sponsor
First posted
Nov 16, 2022
Start date
Jan 2, 2023
Primary completion
Jun 28, 2027 (estimated)
Completion
Jun 28, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Olu Bamgbade, MD, CPI, FRCPC, PMP, DBA
Contact
salem.painclinic@gmail.com
+17786286600
Olu Bamgbade, MD, CPI, FRCPC, PMP, DBA
principal investigator · Salem Anaesthesia Pain Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion